US Far-Right Groups Target The FDA

6 February 1995

The usual US Food and Drug Administration critics who have accused the agency of being either too lenient or too strict, depending on their point of view, are now being replaced by more strident and better-funded groups calling for the restructuring or even the dismantling of the agency.

Citizens for a Sound Economy is devoting a good part of its $10 million budget to this issue, and says plainly that the FDA may be doing more harm than good. House Speaker Newt Gingrich's Progress and Freedom Foundation is spending half a million dollars for a panel, headed by former health and Human Services Secretary Louis Sullivan, to design a drug-approval process that would replace the FDA with a private organization.

Washington Legal Foundation lawyer Daniel Popeo feels that an unelected regulator should not be allowed to have the power to decide who lives and who dies. To this end, the WLF, which campaigns for reduced government, has taken full-page newspaper advertisements aganst the agency in publications such as USA Today, the Wall Street Journal and the National Journal, depicting tombstones and coffins. One ad states: "FDA can delay medications and safety devices for years; too bad it can't delay the consequences," and another says: "If a murderer kills you, its homicide. If a drunk driver kills you, its manslaughter. If the FDA kills you, it's just being cautious."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight